Drug Trial Radar · NCT03124407
Osteoarthritis Knee Pain Relief Study of 0.25% 920-CGS-200
Last checked: Nov 20, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Jul 2016
Primary completion
Oct 2016
Study completion Oct 2016
Sponsor
- Lead sponsor
- Propella TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Palm Beach Research, Inc
- First posted
- Apr 21, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study of an over-the-counter, capsaicin-based (0.25%) topical analgesic for management of osteoarthritis knee pain meeting the US Food and Drug Administration's (FDAs) Tentative Final Monograph (TFM) guidance for "External Analgesic Drug Products For Over-the-Counter Human Use," published in the Federal Register on February 8, 1983 (final proposed 21 CFR 348). Subjects meeting the inclusion criteria and not meeting the exclusion criteria were randomized into one of four groups: once daily treatment with active product, once daily treatment with product vehicle (no capsaicin), twice daily treatment with active product, and twice daily treatment with product vehicle (no capsaicin), all for 7 consecutive days of treatment. The twice daily treatments were spaced approximately 12 hours apart. Osteoarthritis knee pain was assessed by the 100 mm visual analog scale. Osteoarthritis knee pain assessments were done each day for 28 days. Tolerability data were also collected.
Conditions
- Osteoarthritis, Knee
Interventions
Capsaicin Topical SolutionDrug
Over-the-counter Tentative Final Monograph compliant product with 0.25% capsaicin
Drug product vehicleOther
This is the vehicle for the active treatment drug product, but without capsaicin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With 50% or Greater Pain Score Reduction From Baseline to 24 Hours After First Dose of Study Drug Treatment.Time frame: Study Day 2
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Research Center
Clearwater, Florida
Research Center
Tampa, Florida
Research Center
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.